Myeg returned for augmented reality technology developer HiScene's $41.6m series C-plus round while celiac disease drug developer Calypso Biotech hiked a corporate-backed round to over $33m.
Funding
China-based augmented reality technology developer HiScene has closed a RMB270m ($41.6m) series C-plus round featuring IT services firm Myeg and digitalisation technology provider Esmartwave, China Money Network reported today. Citic PE led the round, which included Jadex Capital, V Star Capital, Sincere Capital and Ondice Capital. It came after a $35m series C round in 2019 led by Yangtze River Delta Collaborative Advantage Industry Fund and backed by Panxi Capital, taking HiScene’s total funding to over $67m.
Netherlands-based…
